<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="169945">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884286</url>
  </required_header>
  <id_info>
    <org_study_id>APL-B-013-02</org_study_id>
    <nct_id>NCT00884286</nct_id>
  </id_info>
  <brief_title>Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma</brief_title>
  <official_title>A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter study to assess the anti-tumour activity,to investigate the safety
      profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour
      weekly IV infusion in patients with aggressive non-Hodgkin's Lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A
      1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory aggressive non-Hodgkin's
      Lymphoma.

      Primary

      • To assess the anti-tumour activity of Aplidin® given as a 1-hour weekly IV infusion, in
      patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy.

      Secondary

        -  To further investigate the safety profile of Aplidin® given as 1-hour weekly IV
           infusion in this patient population.

        -  To obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV
           infusion in patients with aggressive non-Hodgkin's Lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the anti-tumour activity of Aplidin® given as a 1-hour weekly IV infusion, in patients with aggressive non-Hodgkin's Lymphoma, relapsing or refractory to a prior therapy.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety profile of Aplidin® in the patient population and to obtain additional pharmacokinetic information for the drug</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm One</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aplidin® given as a 1-hour weekly IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aplidin®</intervention_name>
    <description>Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.</description>
    <arm_group_label>Arm One</arm_group_label>
    <other_name>plitidepsin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histologically confirmed aggressive lymphomas,

          -  Patient requires treatment because NHL relapses

          -  Measurable disease

          -  Recovery from any non-hematological toxicity derived from previous treatments. The
             presence of alopecia and NCI-CTC grade &lt; 2 symptomatic peripheral neuropathy is
             allowed.

          -  Age &gt; 18 years.

          -  Performance status (ECOG) &lt; 2

          -  Adequate renal, hepatic, and bone marrow function (assessed &lt; 14 days before
             inclusion in the study)

          -  Left ventricular ejection fraction within normal limits.

        Exclusion Criteria:

          -  Prior therapy with Aplidin®.

          -  Concomitant therapy with any anti-lymphoproliferative agent

          -  Acute lymphoblastic leukemia.

          -  CNS lymphoma.

          -  HIV-associated lymphoma.

          -  Prior gene therapy with viral vectors.

          -  More than three previous lines of systemic biological agents or chemotherapies.
             Wash-out periods since the end of the precedent therapy less than:

               -  6 weeks for nitroso-urea or high dose chemotherapy

               -  3 weeks for other chemotherapies or biological agents

               -  4 weeks for radiation or radionuclide therapy (6 weeks in case of prior
                  extensive external beam radiation (more than 25% of bone marrow distribution).

               -  4 weeks for major prior surgery

               -  30 days for any investigational product

               -  4 weeks for immunosuppressive therapy after allogeneic hematopoietic stem cell
                  transplantation.

          -  Pregnant or lactating women.

          -  Men and women of reproductive potential who are not using effective contraceptive
             methods

          -  History of another neoplastic disease. Exceptions: Non-melanoma skin
             cancer,cCarcinoma in situ of any site,any other cancer curatively treated and no
             evidence of disease for at least 10 years.

          -  Known cerebral or leptomeningeal involvement.

          -  Other relevant diseases or adverse clinical conditions

          -  Treatment with any investigational product in the 30 days period before inclusion in
             the study.

          -  Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol

          -  Limitation of the patient's ability to comply with the treatment or follow-up
             protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Ribrag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Gustave Roussy, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint- Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di ematologia e oncologia medica &quot;L. e. A. Seragnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedaliero Universitaria de Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Especialidades Médicas Universal S.A.</name>
      <address>
        <city>San Borja - Lima</city>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Español Auxilio Mutuo de Puerto Rico Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00919</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>3008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37707</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>CH-6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 10, 2011</lastchanged_date>
  <firstreceived_date>April 17, 2009</firstreceived_date>
  <responsible_party>
    <name_title>PharmaMar USA Inc</name_title>
    <organization>PharmaMar USA Inc</organization>
  </responsible_party>
  <keyword>Aplidin</keyword>
  <keyword>Aggressive Non Hodgkin Lymphoma</keyword>
  <keyword>Leukemia-Lymphoma, Adult T-Cell and B-cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
